ConcertAI Expands CancerLinQ Suite with AI-Driven Trial Matching and Contextualized Patient Insights to Support Oncologists at the Point of Care

New capabilities identify trial-eligible patients 3.3x faster and surface real-world cohort comparisons from over 13 million patient records, directly within the clinical workflow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI^®, the real‑world healthcare intelligence company for those advancing research, treatment, and care in oncology and other complex diseases, is unveiling enhancements to its CancerLinQ® Suite at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The new capabilities leverage clinically intelligent AI to parse through large volumes of structured and unstructured data on a weekly basis, giving oncologists and clinical care teams faster, more contextualized intelligence to support clinical trial matching and treatment decisions, all within their existing workflow.

Oncology care teams are navigating an increasingly complex treatment landscape, with new biomarkers, expanding lines of therapy, and a growing trial ecosystem that demands faster, more precise decisions during time-constrained patient encounters. ConcertAI's proprietary dataset draws from more than 13 million patient records across all 50 states to deliver one of the industry's most comprehensive real-world resources for quality benchmarking and clinical research. Through AI-driven curation of unstructured data into actionable insights, the CancerLinQ Suite unifies quality governance, clinical decision support, and trial optimization into a single solution that helps improve patient outcomes.

“The promise of technology in oncology isn't measured by how sophisticated the platform is, but instead by whether it meaningfully supports the clinicians delivering care and positively impacts patient outcomes,” said Shaalan Beg, M.D., Chief Medical Officer, Oncology, ConcertAI. “Our newest CancerLinQ enhancements were built to put trial matching and real-world cohort comparisons directly in the workflow, where they can actually inform treatment decisions. That's the standard we hold ourselves to: AI that earns its place at the bedside.”

Streamlining Trial Enrollment Through Workflow-Integrated AI

The CancerLinQ Suite's TriaLinQ™ module now offers powerful new patient eligibility matching capabilities, driven by advanced AI models that pinpoint the clinical factors that determine clinical trial eligibility, such as line of therapy, progression, recurrence, and nuanced biomarker profiles. By automating the screening process, the platform helps screen eligible patients 3.3 times faster than traditional manual methods. Integrating these actionable insights directly into the clinical workflow supports up to 50% higher clinical trial enrollment, ultimately helping expand patient access to leading-edge therapies.

Contextualized Insights for Confident Treatment Decisions

The CancerLinQ Suite's PatientLinQ™ module provides a comprehensive, 360-degree view of patient care, deeply rooted in biomarker insights. In addition to quickly identifying clinical trials where patients have a 90% or greater likelihood of eligibility, it seamlessly aligns these opportunities with specific clinical contexts. This empowers clinicians to:

• Compare individual patients against real-world cohorts drawn from a robust dataset of over 13 million patient records to evaluate standard treatments and outcomes
• Identify and close critical care gaps in testing or treatment delivery before they impact the patient journey
• Make fast, confident, and informed decisions during critical treatment periods to ensure the best possible outcomes for every patient

The CancerLinQ Suite is powered by Cara™, ConcertAI's proprietary agentic AI platform, which curates unstructured clinical data into actionable, explainable insights trained specifically for oncology use cases. Together, TriaLinQ and PatientLinQ build on the broader CancerLinQ Suite, which sources longitudinal oncology data from more than 900 sites of care to deliver a learning intelligence platform connecting clinical excellence, shared learning, and groundbreaking research.

Interested audiences can see the enhanced CancerLinQ Suite live at ASCO 2026 in booth #12131, May 29 – June 2, in Chicago. To learn more, visit concertai.com/cancerlinq.

About ConcertAI

ConcertAI is the real-world healthcare intelligence company for those advancing research, treatment, and care in oncology and other complex diseases. Built on proprietary, comprehensive clinical and genomic datasets, advanced imaging, and deep multidisciplinary expertise, ConcertAI orchestrates clinical expertise, comprehensive real-world data, and applied AI into a system that works in concert across research, development, and care. Its proprietary Cara^TM platform operationalizes this orchestration to deliver explainable, defensible insight clinical and life science teams can rely on and put into practice with confidence. Working with 75% of the top 30 life sciences organizations, more than 2,000 healthcare providers and medical societies, and a trusted ecosystem of scientific and technology partners, ConcertAI has built the market's most comprehensive real-world data sets, proven every day at enterprise scale. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, and Tokyo. Learn more at www.concertai.com.